What type of study is this?

This is a Phase 2 study (also classified as: Human Clinical Trial).

August 22, 2025Open Access

Suzetrigine as a Novel Non-opioid Analgesic Drug in Pain Management: A Review of Clinical Evidence and Therapeutic Perspectives

Key Points

Suzetrigine offers effective pain relief, minimizing adverse effects compared to traditional opioids.
Phase II and III trials reported high efficacy in postoperative pain management with rare mild side effects.
Assessment of pharmacokinetics and ongoing studies are critical for safety evaluation in diverse patient populations.
Highlights the potential of suzetrigine as a safer, non-opioid option in chronic pain therapy.

Abstract

The NaV1.8 sodium channel plays a key role in the transmission of pain signals in peripheral sensory neurons. Suzetrigine is a selective NaV1.8 inhibitor developed as a non-opioid analgesic. Its action is limited to sensory neurons, reducing the risk of adverse effects associated with non-selective sodium channel blockers. Phase II and III clinical trials have demonstrated the high efficacy of suzetrigine in managing postoperative pain, along with good tolerability. Adverse events, such as dizziness or drowsiness, were rare and generally mild to moderate in intensity. The drug did not cause respiratory depression or addiction, which distinguishes it from opioids. Ongoing pharmacokinetic studies and long-term observations aim to further define the drug's safety profile and its potential use in patients with comorbid conditions. Suzetrigine may offer an effective and safe alternative to opioids in pain treatment.

Read Full Paperexternally

Demander à l'IA

Bookmark

View Full Paper